117 related articles for article (PubMed ID: 35285156)
1. Patient-derived organoids, creating a new window of opportunities for pancreatic cancer patients.
Sandhya S; Hogenson TL; Fernandez-Zapico ME
EMBO Mol Med; 2022 Apr; 14(4):e15707. PubMed ID: 35285156
[TBL] [Abstract][Full Text] [Related]
2. Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response.
Frappart PO; Walter K; Gout J; Beutel AK; Morawe M; Arnold F; Breunig M; Barth TF; Marienfeld R; Schulte L; Ettrich T; Hackert T; Svinarenko M; Rösler R; Wiese S; Wiese H; Perkhofer L; Müller M; Lechel A; Sainz B; Hermann PC; Seufferlein T; Kleger A
United European Gastroenterol J; 2020 Jun; 8(5):594-606. PubMed ID: 32213029
[TBL] [Abstract][Full Text] [Related]
3. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer.
Grossman JE; Muthuswamy L; Huang L; Akshinthala D; Perea S; Gonzalez RS; Tsai LL; Cohen J; Bockorny B; Bullock AJ; Schlechter B; Peters MLB; Conahan C; Narasimhan S; Lim C; Davis RB; Besaw R; Sawhney MS; Pleskow D; Berzin TM; Smith M; Kent TS; Callery M; Muthuswamy SK; Hidalgo M
Clin Cancer Res; 2022 Feb; 28(4):708-718. PubMed ID: 34789479
[TBL] [Abstract][Full Text] [Related]
4. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems.
Peschke K; Jakubowsky H; Schäfer A; Maurer C; Lange S; Orben F; Bernad R; Harder FN; Eiber M; Öllinger R; Steiger K; Schlitter M; Weichert W; Mayr U; Phillip V; Schlag C; Schmid RM; Braren RF; Kong B; Demir IE; Friess H; Rad R; Saur D; Schneider G; Reichert M
EMBO Mol Med; 2022 Apr; 14(4):e14876. PubMed ID: 35119792
[TBL] [Abstract][Full Text] [Related]
5. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Organoid Pharmacotyping Guides Precision Medicine for Pancreatic Cancer.
Zhang Y; Houchen CW; Li M
Clin Cancer Res; 2022 Aug; 28(15):3176-3178. PubMed ID: 35617521
[TBL] [Abstract][Full Text] [Related]
7. Precision Medicine in Pancreatic Cancer: Patient-Derived Organoid Pharmacotyping Is a Predictive Biomarker of Clinical Treatment Response.
Seppälä TT; Zimmerman JW; Suri R; Zlomke H; Ivey GD; Szabolcs A; Shubert CR; Cameron JL; Burns WR; Lafaro KJ; He J; Wolfgang CL; Zou YS; Zheng L; Tuveson DA; Eshlemann JR; Ryan DP; Kimmelman AC; Hong TS; Ting DT; Jaffee EM; Burkhart RA
Clin Cancer Res; 2022 Aug; 28(15):3296-3307. PubMed ID: 35363262
[TBL] [Abstract][Full Text] [Related]
8. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo modeling of acquired drug resistance in BRAF - mutated pancreatic cancer organoids uncovers individual therapeutic vulnerabilities.
Steiner S; Pliego-Mendieta A; Haberecker M; Hussung S; Kollár A; Fritsch R; Arnold F; Lenggenhager D; Planas-Paz L; Pauli C
Cancer Lett; 2024 Mar; 584():216650. PubMed ID: 38246222
[TBL] [Abstract][Full Text] [Related]
10. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma.
Kang Y; Deng J; Ling J; Li X; Chiang YJ; Koay EJ; Wang H; Burks JK; Chiao PJ; Hurd MW; Bhutani MS; Lee JH; Weston BR; Maitra A; Ikoma N; Tzeng CD; Lee JE; DePinho RA; Wolff RA; Pant S; McAllister F; Katz MH; Fleming JB; Kim MP
J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36282600
[TBL] [Abstract][Full Text] [Related]
11. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
12. Auranofin repurposing for lung and pancreatic cancer: low CA12 expression as a marker of sensitivity in patient-derived organoids, with potentiated efficacy by AKT inhibition.
Deben C; Boullosa LF; Fortes FR; De La Hoz EC; Le Compte M; Seghers S; Peeters M; Vanlanduit S; Lin A; Dijkstra KK; Van Schil P; Hendriks JMH; Prenen H; Roeyen G; Lardon F; Smits E
J Exp Clin Cancer Res; 2024 Mar; 43(1):88. PubMed ID: 38515178
[TBL] [Abstract][Full Text] [Related]
13. PDX-derived organoids model in vivo drug response and secrete biomarkers.
Huang L; Bockorny B; Paul I; Akshinthala D; Frappart PO; Gandarilla O; Bose A; Sanchez-Gonzalez V; Rouse EE; Lehoux SD; Pandell N; Lim CM; Clohessy JG; Grossman J; Gonzalez R; Del Pino SP; Daaboul G; Sawhney MS; Freedman SD; Kleger A; Cummings RD; Emili A; Muthuswamy LB; Hidalgo M; Muthuswamy SK
JCI Insight; 2020 Nov; 5(21):. PubMed ID: 32990680
[TBL] [Abstract][Full Text] [Related]
14. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy.
Choi D; Gonzalez-Suarez AM; Dumbrava MG; Medlyn M; de Hoyos-Vega JM; Cichocki F; Miller JS; Ding L; Zhu M; Stybayeva G; Gaspar-Maia A; Billadeau DD; Ma WW; Revzin A
Adv Sci (Weinh); 2024 Feb; 11(5):e2303088. PubMed ID: 38018486
[TBL] [Abstract][Full Text] [Related]
15. [Organoids from pancreatic ductal adenocarcinoma].
Dusetti N; Iovanna J
Med Sci (Paris); 2020 Jan; 36(1):57-62. PubMed ID: 32014099
[TBL] [Abstract][Full Text] [Related]
16. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Fluid Hyperthermia as Treatment Option for Pancreatic Cancer Cells and Pancreatic Cancer Organoids.
Palzer J; Mues B; Goerg R; Aberle M; Rensen SS; Olde Damink SWM; Vaes RDW; Cramer T; Schmitz-Rode T; Neumann UP; Slabu I; Roeth AA
Int J Nanomedicine; 2021; 16():2965-2981. PubMed ID: 33935496
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
19. Shared extracellular vesicle miRNA profiles of matched ductal pancreatic adenocarcinoma organoids and blood plasma samples show the power of organoid technology.
Zeöld A; Sándor GO; Kiss A; Soós AÁ; Tölgyes T; Bursics A; Szűcs Á; Harsányi L; Kittel Á; Gézsi A; Buzás EI; Wiener Z
Cell Mol Life Sci; 2021 Mar; 78(6):3005-3020. PubMed ID: 33237353
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]